Omeros Corporation has taken a significant step in aligning executive compensation with company performance by granting a performance-based stock option to its CEO, Gregory A. Demopulos. This decision, made by the company's Compensation Committee, aims to incentivize Dr. Demopulos to drive stock price appreciation and enhance shareholder value.

The performance award consists of an option to purchase up to 500,000 shares of Omeros' common stock. Importantly, this award will only vest upon meeting specific stock price performance hurdles and continued service conditions. The exercise price for these options is set at $17.88 per share, reflecting the company's closing stock price on the grant date.

This strategic move comes after a year of transformative changes for Omeros, including the FDA approval of its drug YARTEMLEA and the completion of a significant asset sale to Novo. The Compensation Committee believes that the performance award is in the best interests of the company, as it recognizes Dr. Demopulos' contributions while also ensuring that his future compensation is tied to the company's performance.

Background

Omeros Corporation, incorporated in Washington, operates within the pharmaceutical preparations sector (SIC 2834). The company is publicly traded on the Nasdaq under the ticker symbol OMER. Omeros focuses on developing and commercializing innovative therapeutics for various medical conditions.

What the Filing Says

According to the recent SEC filing, the Compensation Committee granted the performance award on October 28, 2026. The award's vesting is contingent upon achieving stock price hurdles of $25.00, $30.00, $35.00, and $40.00 per share. These hurdles represent significant appreciation targets of approximately 40%, 68%, 96%, and 124%, respectively, above the grant-date closing price.

Impact

This performance award is likely to impact not just Dr. Demopulos but also Omeros' shareholders, as it aims to drive long-term stock price appreciation. The structure of the award may also influence how other companies in the pharmaceutical industry approach executive compensation, particularly in terms of aligning pay with performance metrics.

What's Next

The filing does not say what happens next.